Decreased CD5+ B Cells in Active ANCA Vasculitis and Relapse after Rituximab

Donna O’Dell Bunch,* JulieAnne G. McGregor,* Nirmal B. Khandoobhai,* Lydia T. Aybar,* Madelyn E. Burkart,* Yichun Hu,* Susan L. Hogan,* Caroline J. Fouton,* Elisabeth A. Berg,* Ronald J. Falk,* and Patrick H. Nachman*

Summary

Background and objectives B cell significance in ANCA disease pathogenesis is underscored by the finding that ANCA alone can cause disease in mouse models and by the effectiveness of rituximab as therapy in ANCA-small vessel vasculitis (ANCA-SVV). To avoid infections and adverse events from therapy, clinicians require improved markers of disease activity and impending relapse to guide immunosuppression strategies after rituximab treatment.

Design, setting, participants, & measurements The B cell phenotype was investigated in patients with active ANCA-SVV and in remission. From 2003 to 2009, 54 patients were followed longitudinally for 4–99 months and compared with 68 healthy controls. In a subset of 19 patients, the B cell immunophenotype was examined in samples after rituximab therapy.

Results Patients with active ANCA-SVV had lower %CD5+ B cells, whereas %CD5+ B cells from patients in remission were indistinguishable from healthy controls. After rituximab, median time to relapse was 31 months in patients maintaining normalized %CD5+ B cells, with or without maintenance immunosuppression. Among patients whose B cells repopulated with low %CD5+ B cells or had a sharply declining %CD5+ B cells, those who were on low or no maintenance immunosuppression relapsed sooner (median 17 months) than patients who were maintained on high levels of oral maintenance immunosuppression (29 months; P=0.002).

Conclusions The %CD5+ B cells, as a component of the human B regulatory cell phenotype, is a useful indicator of disease activity, remission, and future relapse, and thus may guide remission maintenance therapy after rituximab treatment.

Introduction

ANCA-small vessel vasculitis (ANCA-SVV) is a severe relapsing disease wherein B cells produce autoantibodies directed against myeloperoxidase (MPO) (1) or proteinase 3 (PR3) (1,2). These autoantibodies can cause disease in mouse models (3–5). Recently, rituximab (a B cell–depleting mAb) has been shown to be effective in treating ANCA-SVV, suggesting that B cells play an important role in the pathophysiology of this disease (6,7). We predicted that B cell phenotype might be used as an indicator of disease activity, response to treatment, or future relapse. CD5 mutes B cell signaling and maintains immune tolerance via anergy (8–12). Recently, human B regulatory (Breg) cells characterized as CD24hi and either CD38hi (13) or CD27+ (14) were described. These cells are also noted to be CD5+ (13). We investigated CD5+ B cells in patients during the course of disease activity and with response to rituximab therapy.

We report a B cell population that partially overlaps with the immunophenotype for regulatory B cells and correlates with disease activity in patients with ANCA-SVV. To further evaluate the relationship of CD5+ B cells and states of remission and relapse in ANCA-SVV, we examined peripheral blood samples from patients who received rituximab therapy and underwent B cell depletion. We hypothesized that patients who repopulated with normalized %CD5+ B cells after rituximab would have a more sustained remission than patients who repopulated with low %CD5+ B cells.

Materials and Methods

Patient and Healthy Control Samples

We performed flow cytometry analysis of lymphocyte samples from 54 patients with ANCA-SVV and 68 healthy controls between the years 2003 and 2009. Informed consent was obtained in accordance with our institutional review board’s guidelines for human participants. Peripheral blood samples were collected from patients positive for MPO-ANCA and/or PR3-ANCA by either indirect immunofluorescence or antigen-specific ELISA. Patients with Churg-Strauss syndrome or anti-glomerular basement membrane or overlap ANCA/anti-glomerular basement membrane

*UNC Kidney Center, and †Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina

Correspondence: Dr. Donna O’Dell Bunch, UNC Kidney Center, University of North Carolina, 5005 Burnett-Womack Building, CB# 7155, Chapel Hill, NC 27599. Email: donna_bunch@med.unc.edu
disease were excluded. Forty-nine of 54 patients had biopsy-proven ear, nose, and throat, pulmonary, renal, or dermatologic small vessel vasculitis. Clinical and serological data were gathered during routine clinic visits at the time of blood draw for B cell analysis. Patients with end stage kidney disease were excluded from this study unless there were overt extrarenal manifestations of vasculitis.

Patient Groups

Vasculitis disease activity was measured using the Birmingham Vasculitis Activity Score (BVAS) (15). Patients with a BVAS ≥1 were considered to have active disease. When possible, "active" samples were obtained at disease onset; otherwise, the sample corresponding to the highest BVAS score was used in these analyses. Samples were classified as "remission" if patients were in remission for 3 months before and after the collection date. Active versus remission samples were compared in rituximab-naïve patients.

When available, blood samples were evaluated before and after rituximab treatment. We examined the last obtained before rituximab treatment and samples obtained after rituximab treatment in which the %CD19+ B cells were ≥1%. For post-rituximab evaluation, patients were separated into three groups. Patients whose %CD5+ B cells measured >30% ("normal" based on the mean of healthy controls) at the time of B cell repopulation and in the samples after B cell repopulation were labeled group 1 regardless of remission maintenance therapy dose. Patients whose %CD5+ B cells measured ≤30% at the time of B cell repopulation, or decreased to ≤30% within 12 months, were subdivided based on the dose of mycophenolate mofetil (MMF) received after rituximab treatment. Patients who had low-dose MMF (<1 g/d) were labeled group 2, whereas those maintained on higher doses of MMF (>1 g/d) after rituximab infusion were labeled group 3. Only two of our patients were taking any steroids as part of their maintenance therapy and this dose was quite minimal, we did not consider the prednisone dose in our division of patients with low %CD5+ B cells into low and high immunosuppression subgroups (groups 2 and 3).

We performed a sensitivity analysis by regrouping the patients based on CD5+ B cells at the time of B cell repopulation only, without considering the subsequent trend of CD5+ B cells, and then reanalyzing the data as done for the primary analysis.

Cell Preparation and Cell Surface Staining

PBMCs were purified from heparinized peripheral blood samples by centrifugation in cell preparation tubes (Becton Dickinson and Company, Franklin Lakes, NJ). Cells were washed in PBS, resuspended in Hank's buffered salt solution (2% FCS, 0.1% sodium azide) and stained with CD19-APC (HIB19) in combination with two of the following either FITC- or PE-fluorescently labeled antibodies to CD21 (B-ly4), CD24 (ML5), CD27 (M-T271), CD38 (HIT2), CD5 (UCHT2), IgM (G20–127), or IgD (IA6–2) (BD Pharmingen, San Diego, CA). After fixation with 1% paraformaldehyde, cells were analyzed using a FACSCalibur flow cytometer. B cells were gated based on CD19+ staining. Data were analyzed with Summit (DakoCytomation, Carpinteria, CA) or FlowJo (Treestar, Ashland, OR) software.

Statistical Analyses

Mean ± SD or median and interquartile range (IQR) were used to describe demographic and clinical characteristics as appropriate. Wilcoxon rank-sum or Kruskal–Wallis tests were used to compare groups for continuous variables, and Fisher’s exact tests were used for categorical variables. We used the paired Wilcoxon signed rank test to evaluate the paired difference of B cell phenotypes in the subgroups. P values reported with a two-sided P value of ≤0.05 indicate a significant difference. Analyses were conducted using SAS 9.1 software (SAS Institute, Cary, NC).

Results

The %CD5+ B Cells Is Reduced in Patients with Active Disease and Before Relapse

We first examined %CD5+ B cell expression in rituximab-naïve ANCA-SVV patients. Samples were evaluated at the time of either active disease (BVAS ≥1, n=24) or remission (BVAS=0, n=19) (Table 1). There were no significant differences between active disease patients compared with those in remission with respect to age, sex, ethnicity, ANCA type, disease category, organ involvement, or peak creatinine at disease onset (Table 1). Patients with active disease had significantly lower %CD5+ B cells (median 17%; IQR, 10, 28) than those in remission (26%; IQR, 21, 36; P=0.02) and healthy controls (28%; IQR, 21, 35; P=0.001) (Figure 1A, Table 1). The %CD5+ B cells during remission did not differ significantly from the percentage found in healthy controls. Although patients were significantly older than healthy controls, the %CD5+ B cells did not correlate with age in healthy controls, patients with active disease or patients in remission (data not shown). In patients for whom active and remission samples were available, the %CD5+ B cells increased from a median of 14% (IQR, 10, 17) in active disease to a median of 25% (IQR, 17, 45; P=0.008) as patients entered remission (Figure 1B). When %CD5+ B cells were compared with disease activity over time, downward trends in CD5 were associated with relapse (representative Figure 1C). An example of a patient who maintained >30% of CD5+ B cells and remained in remission without maintenance immunosuppression with a persistently high MPO-ANCA titer for 82 months is shown in Figure 1D.

B Cell Phenotypes after Rituximab Therapy

To further elucidate the relationship between %CD5+ B cells and disease activity, we studied a subset of 19 patients who received rituximab (Table 2). The %CD5+ B cells were measured following B cell repopulation after rituximab. Group 1 (patients who repopulated with >30% CD5+ B cells) was diverse with regard to MMF dose; there were
three patients on no immunosuppression, two patients on low immunosuppression, and two patients on high immunosuppression with a mean dose of 0.75 ± 0.8 g/d (Table 2). By definition, patients who repopulated with ≤30% CD5+ B cells and were maintained on ≤1 g/d MMF (group 2) were prescribed 75% less MMF (mean 0.43 ± 0.5 g/d) than group 3 patients who also repopulated with ≤30% CD5+ B cells but were maintained on >1 g/d MMF (mean 1.95 ± 0.7 g/d) (P = 0.01). On average, group 2 and group 1 were similar with regard to immunosuppression dose (P = 0.4). All patients treated with oral remission maintenance therapy after rituximab infusion were prescribed MMF with the exception of two patients who received low-dose cyclosporine (<1 mg/kg per day) in addition to MMF. Patient characteristics were similar across the three groups (Table 2).

Group 1 had a significantly higher %CD5+ B cells (median 57%; IQR, 48, 70) at the time of B cell repopulation than group 2 (18%; IQR, 11, 31; P = 0.003) (Table 2). Group 3 had a similarly low %CD5+ B cells (23%; IQR 13, 53) but did not reach statistical significance due to the small number of patients. The median %CD5+ B cells at the last sample available before flare for group 1 was 34% CD5+ B cells (IQR, 27, 41). The median %CD5+ B cells at the time proximal to flare was 16% (IQR, 15,18) and 4% (IQR, 4, 16) for groups 2 and 3, respectively. Time to relapse after rituximab infusion was significantly shorter when CD5 was ≤30% at the time of B cell repopulation (group 2) (P = 0.002; Table 2). In patients who had CD5 levels >30% at the time of B cell repopulation and remained >30% for all subsequent samples evaluated (group 1), but similarly low levels of oral remission maintenance therapy, time to flare was 18 months longer on average than group 2 (Table 2). Group 3 patients had similarly low CD5 levels to group 2 patients (P = 0.52), but were maintained on significantly higher doses of MMF (P = 0.01). Their time to flare after rituximab infusion was on average 20 months longer than group 2 (P = 0.01; Table 2). Time to flare from B cell repopulation was also significantly different between group 2 patients and either patients whose %CD5+ B cells remained >30% after B cell repopulation maintained on similarly low remission maintenance therapy (P = 0.002, group 1) or when oral remission maintenance therapy was maintained at significantly higher doses (group 3) (P = 0.01, Table 2).

### Sensitivity Analyses

Sensitivity analyses were performed to evaluate whether the association between %CD5+ B cells and time to relapse held up after regrouping patients based strictly on %CD5+ B
cells at the time of B cell recovery (Supplemental Table 1). Patients having >30% CD5+ B cells at the time of B cell repopulation became group 1 (n=10) regardless of whether the %CD5+ decreased below 30% subsequently. Group 2 (n=6) had ≤30% CD5+ B cells at B cell repopulation and were on ≤1 g of MMF daily (mean 0.33±0.5 g/d). Group 3 (n=3) had ≤30% CD5+ B cells at B cell repopulation and were on >1 g of MMF daily (mean 2±1 g/d) (P=0.04 compared with group 2). By definition, group 1 repopulated with higher %CD5+ B cells (median 55%; IQR, 48, 70) compared with both group 2 (17%; IQR, 11, 30) and group 3 (13%; IQR, 12, 23) (P=0.001) after rituximab. The time to flare after rituximab therapy for group 2 was significantly shorter (median 16 months;
IQR, 12, 18) compared with both group 1S (28 months; IQR, 25, 34) and group 3S (35 months; IQR, 29, 65) (\(P=0.002\)). The %CD5+ B cells at the time of documented flare did not differ for group 1S and group 2S (median 26% and 16%, respectively; \(P=0.18\)), whereas the %CD5+ B cells were lower when relapses occurred in group 3S (4%; \(P=0.05\)).

To evaluate %CD5+ B cells with respect to clinical disease activity in patients treated with rituximab, %CD5+ B cells were plotted against BVAS and MMF dose. Three examples depict the consistent decline in %CD5+ B cells that we observed before disease relapse (Figure 2, A–C). Time to relapse appears delayed if higher levels of remission maintenance therapy were given when CD5 levels were 30%.

Other B cell populations—including naïve, switched, and nonswitched memory, IgD,CD27-double negative, and pre-germinal center founder (Bm2"3d) cells—are different in ANCA patients compared with controls but

| Table 2  Comparison of patient groups after treatment with rituximab |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristic  | Group 1 (n=7)   | Repopulation with normal % CD5+ B cells | Repopulation with low % CD5+ B cells (≤30%), low remission maintenance medicationa | Repopulation with low % CD5+ B cells (≤30%), high remission maintenance medicationb | \(P\) Valuec |
| Age             | 59 (32,61)      | 52 (45,59)      | 51 (38,58)      | 0.93            |
| Female          | 1 (14%)         | 6 (86%)         | 2 (40%)         | 0.03            |
| Race            | 6 (86%)         | 6 (86%)         | 4 (80%)         | 0.80            |
| ANCA            | 3 (43%)         | 0 (0%)          | 2 (40%)         | 0.18            |
| MPO             | 4 (57%)         | 6 (86%)         | 3 (60%)         |                 |
| PR3             | 0 (0%)          | 1 (14%)         | 0 (0%)          |                 |
| GPA             | 5 (71%)         | 4 (57%)         | 4 (80%)         | 0.70            |
| MPA             | 1 (14%)         | 3 (43%)         | 1 (20%)         |                 |
| ANCA GN (renal limited) | 1 (14%) | 0 (0%) | 0 (0%) |                 |
| Disease         |                 |                 |                 |                 |
| GPA             | 4 (57%)         | 5 (72%)         | 5 (100%)        | 0.35            |
| Pulmonary       | 5 (71%)         | 7 (100%)        | 3 (60%)         | 0.25            |
| Renal           | 5 (83%)         | 4 (100)         | 4 (80%)         | >0.99           |
| Peak serum creatinine at disease onset (mg/dl) | 1.7 (1.0,2.9) | 2.5 (1.8,2.9) | 1.6 (1.2,1.8) | 0.28 |
| %CD5+ B cells at time of B cell repopulation | 57 (48,70)d | 18 (11,31)e | 23 (13,53)d,e | 0.02 |
| %CD5+ B cells at last sample available prior to flare | 34 (27,41) | 16 (15,18) | 4 (4,16) | 0.06 |
| Dose of MMF for remission maintenance (g/day) | 1.00 (0,1.25)d,e | 0 (0,1.0)d | 2.0 (1.5,2.0)e | 0.007 |
| Time to relapse from rituximab (months) | 31 (25,48)d | 17 (12,20)e | 29 (29,35)d | 0.002 |
| Time to relapse from B cell repopulation (months) | 22 (17,36)d | 7 (3,11)f | 22 (20,27)d | 0.002 |
| Total B cell number (x10^4/ml blood) | 5.7 (2.4,15.0) | 1.7 (1.0,3.2) | 3.9 (2.4,4.5) | 0.15 |
| ANCA titer (U/ml) | 39 (10,95) | 52 (5,71) | 8 (6,24) | 0.28 |

Values for variables examined in patient groups after rituximab therapy are reported as \(n\) (%) or median (interquartile range). MPO, myeloperoxidase; PR3, proteinase 3; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; MMF, mycophenolate mofetil.

aOne group 2 patient was on cyclosporine (50 mg twice daily) and prednisone (6 mg/day).
bOne group 3 patient was on MMF (1 g twice daily) and prednisone (10 mg every other day) after rituximab therapy concurrent with seven monthly intravenous doses of cyclophosphamide.
c\(P\) values were calculated by Fisher exact test for categorical variables and Kruskal-Wallis Test for continuous variables.
d,e Different superscript letters indicate a statistically significant difference between groups after a Bonferroni correction (\(P<0.02\)).
fANCA titer indicates the MPO-ANCA titer for MPO-ANCA patients or the PR3-ANCA titer for PR-3 patients combined together as a group for all patients in either group 1, 2 or 3. ANCA titers were determined by the McLendon Clinical Laboratories at the University of North Carolina using ELISA kits specific for either MPO or PR3 (Inova Diagnostics, San Diego, CA). Negative titers are ≤ 20 U/ml.
do not correlate with disease activity (Supplemental Table 2). CD21 differs between active disease and remission \((P, 0.001)\) but is not clearly associated with time to relapse.

**CD5 as a Surrogate Marker for Putative B Regulatory Cells**

Because of its role as a negative regulator of B cell receptor signaling and its inclusion in the immunophenotype reported for Breg cells, we compared CD5\(^+\) B cells with other phenotypes reported for Breg cells. CD5\(^+\) B cells correlate well with the CD24\(^{hi}\)CD38\(^{hi}\) population of Breg cells that has been shown to secrete IL-10 \((R^2=0.50; \text{Figure 3A})\) in all samples for which both stains were available (21 healthy controls, 17 with active disease, 13 in remission). When flow cytometric data were available for all three stain sets (CD24\(^{hi}\)CD38\(^{hi}\),...
These B cell populations correlated well over time (representative patients shown in Figure 3B). In the last 2 decades, marked improvement has been observed in the induction treatment of patients with ANCA vasculitis, with remission rates around 80% (16–18). A major remaining challenge in the long-term management of patients pertains to the prevention and treatment of relapses. The risk of relapse is not uniform for all patients with ANCA vasculitis. PR3-ANCA (compared with MPO-ANCA), lung disease, upper respiratory tract disease, a clinical diagnosis of granulomatosis with polyangiitis (compared with microscopic polyangiitis or renal limited disease), cardiovascular involvement, and a lack of renal impairment (creatinine <200 μmol/L) have been reported as risk factors for relapse (19–21). Nevertheless, no clinical or serologic measure is currently available that allows effective disease monitoring and distinguishes patients in relapse from remission.

**Figure 3.** The %CD5+ B cells reflect putative B regulatory cells. (A) The %CD5+ B cells correlates with the percentage of B regulatory cells identified as CD24hiCD38hi B cells (R²=0.50). This correlation includes all samples for which both CD19+CD5+ and CD19+CD24hiCD38hi data were available (21 healthy controls, 17 with active disease, 13 in remission). (B) The correlation between percentages of CD24hiCD38hi (dash-dot line), IgM+CD5+ (dash-dash line), and CD5+ B cells (solid line) are shown for two representative patients for whom all three stain sets were available.
long-term stable remission from those at imminent risk of relapse (22–26). Such a tool would allow physicians to better tailor the duration and intensity of immunosuppressive therapy based on the individual patient’s needs. Our goal was to evaluate whether certain B cell subpopulations could be used to assess immunologic disease activity or a patient’s risk of relapse. Although limited to a small number of patients, we determined that a low percentage (<30%) of circulating CD5+B cells correlates with disease activity and a shorter time to relapse. Patients in remission had %CD5+B cells similar to healthy controls and significantly higher than patients with active disease. After rituximab therapy, low or declining %CD5+B cells was associated with a shorter time to disease relapse among patients on no or low-dose maintenance therapy with MMF. The use of full-dose MMF was associated with a longer time to relapse in the setting of a low %CD5+B cells. Additional data will be required to definitively address the correlation of %CD5+B cells with sustained remission.

If our findings are confirmed in a larger population, then the clinical implications of our results may pertain to the decision to use maintenance immunosuppression after rituximab therapy and its timing. Our data suggest that patients whose %CD5+B cells remain low or decline after a period of normalization after rituximab therapy would be at higher risk of subsequent relapse and would likely benefit from maintenance immunosuppression. Conversely, such immunotherapy could be avoided in patients who maintain a normal %CD5+B cells.

Our results are consistent with current knowledge of B cell subtypes and function. Breg cells, defined by their ability to suppress INF-γ and TNF-α expression in T cells via expression of IL-10, have been described as having a CD24hiCD38hi phenotype (13). Breg cells were also reported to be CD5+IgMhi/hIgDhi/hCD1low/h+CD27negCD1dhi, although consensus on their immunophenotype is not yet fully established (14). We propose that the CD5 marker is an acceptable measure of Breg cells based on our data demonstrating a high correlation with CD24hiCD38hi and IgM+CD5+subpopulations. CD5 is reported to induce IL-10 and expression and promote cell survival in human B cells (27), human chronic lymphocytic leukemia B cells (28), and mice (29). In mice, CD5+CD1d+ B cells secrete IL-10 and have a regulatory function evidenced by their inhibition of INF-γ and TNF-α expression in T cells (30). Our results add to accumulating evidence that a paucity of, or nonfunctional, Breg cells are associated with increased disease activity in autoimmune disease (13,14,31). Years ago, when dogma was pressing of CD5 through methylation changes driven by UNC Kidney Center: Pamela Sullivan and Julie Hamra for help in

Several B cell populations—including naïve, switched, and nonswitched memory, IgD,CD27-double negative, and pregerminal center founder (Bm2/36) cells—have been reported to correlate with response to rituximab therapy in SLE and rheumatoid arthritis (34–36). Neither these B cell populations nor ANCA titer correlated with disease activity or time to flare after rituximab therapy in our patient cohort.

Patients in our study were treated with rituximab for induction of remission after a clinical relapse (to avoid repeat exposure to cyclophosphamide) or because of persistent disease activity despite cyclophosphamide and corticosteroids. Although B cell phenotype data emanate from rituximab-treated patients, they may not be restricted to this form of therapy. Indeed, treatment with cyclophosphamide results in peripheral B cell depletion, albeit more slowly and to a lesser magnitude than with rituximab (6). Studies are ongoing to assess whether similar effects on the CD5+B cell subpopulation are detectable with cyclophosphamide-based therapies.

The optimal choice and duration of maintenance therapy is the subject of current clinical investigations. In this study, the choice of MMF as maintenance therapy after rituximab was not predetermined by protocol, and antedates the published results on the International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Vasculitides study in which azathioprine was associated with a statistically significant decrease in the rate of relapses compared with MMF (24). The demonstrated efficacy of rituximab in treating active ANCA-SVV has raised the question as to its possible role in maintenance therapy, given at regular intervals regardless of clinical signs of disease activity (37). It will be interesting to test the validity of our hypothesis in a setting where a robust CD5+Breg population may be suppressed by a regimen of prolonged B cell depletion. It is possible that a state of immune tolerance may require the presence of robust Breg and/or Treg populations, which would be prevented by sustained B cell depletion.

There are limitations to our study. The relatively small sample size of patients with longitudinal data limits our ability to evaluate the correlation between %CD5+B cells and time to relapse while correcting for other risk factors such as PR3-ANCA, organ involvement, or disease phenotype. Although we attempted to obtain patient samples every 3 months, the timing of our blood collections was not standardized. Samples were obtained from patients whenever they presented for care.

A future research direction will be to validate our findings in a larger cohort of patients treated with either rituximab or cyclophosphamide-based regimens, while formally assessing the time to relapse from the time of decline in %CD5+B cells. We aim to study the relationship between CD5 levels, IL-10–expressing Breg cells, and disease activity in ANCA-SVV. The expression of an alternatively spliced variant of CD5 resulting in reduced membrane expression of CD5 through methylation changes driven by IL-6 was recently described (38), which may regulate the function of Breg cells. The effect, if any, of the CD5 splice variant on disease activity or response to therapy will be interesting to evaluate.

In summary, we identified a CD5+B cell subpopulation as a potential immunologic marker of sustained remission when robust, or a harbinger of subsequent relapse when low or declining. These findings may offer a clinical tool to monitor disease activity and modulate maintenance immunotherapy.

Acknowledgments

We appreciate the help of the following past members of the UNC Kidney Center: Pamela Sullivan and Julie Hamra for help in
consenting patients and obtaining blood samples and Joe Piscitello for technical assistance. We thank Ahinee Amamoo and Hyunsook Chin for preliminary statistical analysis and Carmen Mendoza for help with figure preparation. This work was supported by Program Project Grant P01-DK-30834 from the National Institute for Diabetes and Digestive and Kidney Diseases of the National Institutes of Health and the Vasculitis Foundation.

Portions of this work were previously presented in poster form at the 2007 and 2008 annual meetings of the American Society of Nephrology, held November 2–5, 2007, in San Francisco, California, and November 6–9, 2008, in Philadelphia, Pennsylvania, respectively.

Disclosures

None.

References


**Received:** April 23, 2012  **Accepted:** November 8, 2012

Present address for Dr. Nirmal B. Khandooahai: Wake Forest Baptist Health, Winston Salem, North Carolina.

Published online ahead of print. Publication date available at www.cjasn.org.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.03950412/-/DCSupplemental.